Now Available for Public Comment: Notice of Proposed Rulemaking (NPRM) for FDAAA 801 and NIH Draft Reporting Policy for NIH-Funded Trials

Prevalence of Glucose Intolerance and Risk Factors in Ethiopian Immigrants in Israel; Follow-up Study.

The recruitment status of this study is unknown because the information has not been verified recently.
Verified June 2011 by Hillel Yaffe Medical Center.
Recruitment status was  Not yet recruiting
Sponsor:
Information provided by:
Hillel Yaffe Medical Center
ClinicalTrials.gov Identifier:
NCT01402362
First received: July 24, 2011
Last updated: July 25, 2011
Last verified: June 2011
  Purpose

High risk population: Screening for impaired glucose tolerance.


Condition
Diabetes Mellitus
Glucose Intolerance

Study Type: Observational
Study Design: Observational Model: Cohort
Time Perspective: Prospective

Resource links provided by NLM:


Further study details as provided by Hillel Yaffe Medical Center:

Primary Outcome Measures:
  • Percent of patients with Diabetes Mellitus or impaired glucose tolerance [ Time Frame: Day 1 of study ] [ Designated as safety issue: No ]

Secondary Outcome Measures:
  • Prevalence of hypertension and hyperlipidemia [ Time Frame: Day 1 of study ] [ Designated as safety issue: No ]

Estimated Enrollment: 550
Study Start Date: September 2011
Groups/Cohorts
Ethiopians participating in previous study, year 2000

  Eligibility

Ages Eligible for Study:   25 Years to 90 Years
Genders Eligible for Study:   Both
Accepts Healthy Volunteers:   Yes
Sampling Method:   Non-Probability Sample
Study Population

Ethiopian immigrants to Israel living in Hadera.

Criteria

Inclusion Criteria:

  • Participation in the year 2000 study
  • Signature of Informed Consent Form

Exclusion Criteria:

Pregnancy

-

  Contacts and Locations
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the Contacts provided below. For general information, see Learn About Clinical Studies.

Please refer to this study by its ClinicalTrials.gov identifier: NCT01402362

Contacts
Contact: Anat Jaffe, MD PhD +97246304748 Jaffe@hy.health.gov.il

Locations
Israel
Diabetes and Endocrinology Unit, Hillel Yaffe MC, POB169 Not yet recruiting
Hadera, Israel, 38100
Contact: Anat Jaffe, MD PhD    +97246304748    jaffe@hy.health.gov.il   
Sub-Investigator: Liana Tripto, MD         
Principal Investigator: Anat Jaffe, MD PhD         
Sponsors and Collaborators
Hillel Yaffe Medical Center
  More Information

No publications provided

Responsible Party: Diabetes and Endocrinology Unit, Hillel Yaffe Medical Center
ClinicalTrials.gov Identifier: NCT01402362     History of Changes
Other Study ID Numbers: 56-2011
Study First Received: July 24, 2011
Last Updated: July 25, 2011
Health Authority: Israel: Ministry of Health

Keywords provided by Hillel Yaffe Medical Center:
Ethiopians
Diabetes Mellitus
Glucose tolerance
Israel
Included in the year 2000 study

Additional relevant MeSH terms:
Diabetes Mellitus
Glucose Intolerance
Endocrine System Diseases
Glucose Metabolism Disorders
Hyperglycemia
Metabolic Diseases

ClinicalTrials.gov processed this record on November 24, 2014